Live from Open Targets Platform, fetched 2026-11-11 15:38 UTC. Every row links to its source record.

PRMT2 protein arginine methyltransferase 2

ENSG00000160310 · protein coding · Open Targets profile

Arginine methyltransferase that methylates the guanidino nitrogens of arginyl residues in proteins such as STAT3, FBL, histone H4 (PubMed:19405910). Acts as a coactivator (with NCOA2) of the androgen receptor (AR)-mediated transactivation (PubMed:17587566). Acts as a coactivator (with estrogen) of estrogen receptor (ER)-mediated transactivation (PubMed:12039952). Enhances PGR, PPARG, RARA-mediated transactivation (PubMed:12039952). May inhibit NF-kappa-B transcription and promote apoptosis (PubMed:16648481). Represses E2F1 transcriptional activity (in a RB1-dependent manner) (By similarity). May be involved in growth regulation (By similarity). Involved in PRMT2IP-mediated inhibition of the microglial inflammatory responses through suppression of NF-kappa-B signaling, thereby reducing the production of pro- inflammatory cytokines (PubMed:38892217). {ECO:0000250|UniProtKB:Q9R144, ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:16648481, ECO:0000269|PubMed:17587566, ECO:0000269|PubMed:19405910, ECO:0000269|PubMed:38892217}.

PRMT2: inherited and tumour-mutation evidence across 15 cancers

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC: Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.451090008020401 (upper bound 0.6259099841117859). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of PRMT2's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of PRMT2's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

Drug	Type	Highest stage	Indications	Source records
No drugs or clinical candidates recorded.